Please use this identifier to cite or link to this item:
Title: Molecular modeling studies on human dipeptidyl peptidase iv a novel target for diabetes and obesity
Researcher: S. Janardhan
Guide(s): Dr. Y. Padmanabha Reddy
Keywords: A novel target for diabetes and obesity
Upload Date: 17-Dec-2013
University: Jawaharlal Nehru Technological University, Anantapuram
Completed Date: 05.01.2012
Abstract: The chronic metabolic Type 2 Diabetes mellitus (T2D) is epidemic disease spread all over world characterized by hyperglycaemia, which is a major risk factor for cardiovascular diseases. Proteases are attractive targets for small molecule drug discovery because of their role in metabolism, immune regulation, signal transduction and apoptosis. Dipeptidyl peptidase IV (DPP4) is serine protease enzyme, involved in the degradation of incretin hormones such as glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The inhibition of DPP4 provides a new strategy to prolong the insulinotropic actions of GLP-1 and GIP for the treatment of T2D. Despite intensive efforts for more than two decades relatively very few DPP4 inhibitors have entered into the market and most of them were discontinued from clinical trials because of severe toxicities that are associated with DPP4 isoforms. Hence, the design and development of potent, selective DPP4 inhibitors over DPP8, DPP9 and QPP is a major challenge in current drug discovery. newlineThe aim of this current thesis work could be to lead to a better understanding of the specific concerns on DPP4 activity and selectivity. The understanding of active site residues of DPP4 isoforms, structure activity relationship of inhibitors could help to achieve desired activity, selectivity by introducing specific chemotype with appropriate substitution groups. The purpose of this thesis work is to explore and exploit Molecular modeling approaches such as structure-based design (homology modeling, docking and core hopping), ligand-based design (pharmacophore modeling, QSAR) have been carried out on different classes of DPP4 inhibitors provided substantial design clues for the development of novel, potent, selective DPP4 molecules. newline
Pagination: No.of pages- 209
Appears in Departments:Department of Pharmaceutical Sciences

Files in This Item:
File Description SizeFormat 
01_title page.pdfAttached File63.74 kBAdobe PDFView/Open
02_certificate.pdf47.98 kBAdobe PDFView/Open
03_acknowledgement.pdf6.23 kBAdobe PDFView/Open
04_contents.pdf152.75 kBAdobe PDFView/Open
05_abstract.pdf5.9 kBAdobe PDFView/Open
06_list of figures and tables and graphs.pdf175.34 kBAdobe PDFView/Open
07_chapter 1.pdf1.39 MBAdobe PDFView/Open
08-chapter 2.pdf1.49 MBAdobe PDFView/Open
10_chapter 4.pdf357.48 kBAdobe PDFView/Open
11_chapter 5.pdf450.94 kBAdobe PDFView/Open
12_chapter 6 summary&conclusion.pdf598.96 kBAdobe PDFView/Open
13_references.pdf323.41 kBAdobe PDFView/Open
9_chapter 3.pdf350.15 kBAdobe PDFView/Open

Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.